Abstract:Infection with the hepatitis B virus (HBV) is highly prevalent globally. Over 250 million people suffer from chronic hepatitis B, and more than 800,000 patients die each year due to hepatitis B complications, including liver cancer. Although protective HBV vaccines are recommended for all newborns, global coverage is suboptimal. In adults, sexual transmission is by far the most frequent route of contagion. The WHO estimates that 1.5 million new HBV infections occur annually. Oral nucleos(t)ide analogues entecavir and tenofovir are the most frequent antivirals prescribed as HBV therapy. Almost all patients adherent to the medication achieve undetectable plasma viremia beyond 6 months of monotherapy. However, less than 5% achieve anti-HBs seroconversion, and viral rebound occurs following drug discontinuation. Therefore, nucleos(t)ide analogues need to be lifelong. New long-acting formulations of tenofovir and entecavir are being developed that will maximize treatment benefit and overcome adherence barriers. Furthermore, new antiviral agents are in development, including entry inhibitors, capside assembly modulators, and RNA interference molecules. The use of combination therapy pursues a functional HBV cure, meaning it is negative for both circulating HBV-DNA and HBsAg. Even when this goal is achieved, the cccDNA reservoir within infected hepatocytes remains a signal of past infection, and HBV can reactivate under immune suppression. Therefore, new gene therapies, including gene editing, are eagerly being pursued to silence or definitively disrupt HBV genomes within infected hepatocytes and, in this way, ultimately cure hepatitis B. At this time, three actions can be taken to push HBV eradication globally: (1) expand universal newborn HBV vaccination; (2) perform once-in-life testing of all adults to identify susceptible HBV persons that could be vaccinated (or re-vaccinated) and unveil asymptomatic carriers that could benefit from treatment; and (3) provide earlier antiviral therapy to chronic HBV carriers, as being aviremic reduces the risk of both clinical progression and transmission.

Next-generation sequencing for the diagnosis of hepatitis B: current status and future prospects

Next-generation Sequencing in Study of Hepatitis B Virus Variation

A New Method for Next-Generation Sequencing of the Full Hepatitis B Virus Genome from A Clinical Specimen: Impact for Virus Genotyping

Insights From Deep Sequencing of the HBV Genome—Unique, Tiny, and Misunderstood

Illumina and Nanopore methods for whole genome sequencing of hepatitis B virus (HBV)

Development of A Novel Dna Sequencing Method Not Only for Hepatitis B Virus Genotyping but Also for Drug Resistant Mutation Detection

A Comparative Study on the Characterization of Hepatitis B Virus Quasispecies by Clone-Based Sequencing and Third-Generation Sequencing

Detection of Mixed Infections and Analysis of Sequence Conservation

Evolution and diversity of the hepatitis B virus genome: Clinical implications

Comparison of Next-Generation Sequencing and Clone-Based Sequencing in Analysis of Hepatitis B Virus Reverse Transcriptase Quasispecies Heterogeneity

The Impact of HBV Quasispecies Features on Immune Status in HBsAg+/HBsAb+ Patients With HBV Genotype C Using Next-Generation Sequencing

An Oxford Nanopore Technology-Based Hepatitis B Virus Sequencing Protocol Suitable For Genomic Surveillance Within Clinical Diagnostic Settings

The evolution and clinical impact of hepatitis B virus genome diversity

Current hepatitis B treatment guidelines and future research directions

Design and validation of a clinical DNA sequencing assay for drug-resistance genes in hepatitis B virus

Prospects for Controlling Hepatitis B Globally

Whole genome sequencing of hepatitis B virus (HBV) using tiled amplicon (HEP-TILE) and probe-based enrichment on Illumina and Nanopore platforms.

Single-virion sequencing of lamivudine-treated HBV populations reveal population evolution dynamics and demographic history

Analysis of hepatitis B virus genotyping and drug resistance gene mutations based on massively parallel sequencing.

Prediction of Virological Response by Pretreatment Hepatitis B Virus Reverse Transcriptase Quasispecies Heterogeneity: the Advantage of Using Next-Generation Sequencing.